Safety study of two EBV vaccines in healthy people
This study tests two experimental vaccines (V350A and V350B) designed to prevent Epstein-Barr virus infection. It is looking for healthy adolescents and adults to see if the vaccines are safe and produce a good immune response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You should be in generally good health.
- If you're 18 to 30, your BMI must be between 18 and 38. If you're 12 to 17, your BMI must be between 15 and 38.
- You must not have had mono (glandular fever) in the past year.
- You must not have any condition or be on any treatment that weakens your immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether a new vaccine called V118E is safe and well-tolerated in healthy people. It is for adults who are in good health and have not recently had a pneumococcal infection.
This trial tests an immune therapy made from EBV-targeted T-cells to treat EBV infections that do not improve with standard anti-viral medicines. It may help by strengthening the body’s ability to fight EBV after certain transplants or immune problems.
This trial tests an experimental mRNA vaccine (mRNA-1189) to see if it can prevent Epstein-Barr virus (EBV) infection. It is for healthy adults 18 to 30 years old.
This study tests a new vaccine designed to protect against Epstein-Barr virus (EBV), a common virus that can cause serious illness. You would receive the vaccine and be monitored to see how safe it is and how your immune system responds.
This study tests two experimental vaccines against Epstein-Barr virus (EBV), the germ that causes mono. You may be able to join if you are a healthy adult aged 18–29 and haven't had an EBV vaccine before. The trial will check if the vaccines are safe and trigger an immune response.
This study looks at how the immune system’s antibodies behave after a first-time EBV infection, including whether they mistakenly react with the body’s own tissues. You might be offered a chance to help doctors understand why some people get longer or more intense symptoms from infectious mononucleosis.
Hear when a new Healthy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.